Backing innovation in biotech
- Anders Hove
- Isaac Manke
- Jessica Estus
- Max Lewin
- Rakesh Ahuja
Acorn Bioventures invests across stages in small-cap public and private biotechnology companies focused on bringing novel innovative medicines to patients. Our investment flexibility allows us to provide value across the entire spectrum from seed financings, cross-over financings, IPOs, registered direct offerings, PIPEs, open market purchases, etc.
Management teams of our portfolio companies are our long-term partners and we are proud to be part of the entrepreneurial and pioneering spirit in biotech. Acorn Bioventures is structured to be able to provide committed capital to companies through multiple rounds of financing.
Our investment process is based on fundamental research. We look for paradigm changing medical therapies, undiscovered or underappreciated assets, backed by outstanding teams.
We have over 35-year investment experience, including numerous structured public investments, in excess of forty investments in private biotech or medtech companies, and service on more than a thirty Boards. Most of the private investments went on to complete an IPO and some were acquired while private. Driven by their innovation in medicine, many of these companies have grown into very successful multi-billion-dollar exceptional enterprises with approved therapies.
Examples of recent and past private or small cap public investments include Anacor, Arena, Ascendis, Cardiff Oncology, Chiasma, Eidos (Bridge Bio), Eliem, Freeline, GW Pharma (Jazz Pharma), Neuron23, OnKure, Q32 Bio, Renovacor, Tesaro, etc.
This website is intended solely to provide information regarding Acorn Bioventures' potential capabilities with respect to prospective portfolio investments. No information on this website is intended as, and you should not consider it as, investment advice or tax, accounting or legal advice. Past performance is not a guarantee of future results. This website is not an offer to sell or a solicitation of any offer to buy any security in any Acorn Bioventures fund.